The success of Viagra initially fueled a period of growth for the drug industry, but recent shifts present a complicated picture for those considering a stake. Lower-cost versions are reducing profits, and ongoing litigation add additional complexity to the equation. While some companies could still see gains from adjacent offerings, the broader… Read More